Generic name: DAPAGLIFLOZIN PROPANEDIOL 5mg
Dosage form: tablet, film coated
Medically reviewed on October 20, 2017.
The recommended starting dose of FARXIGA is 5 mg once daily, taken in the morning, with or without food. In patients tolerating FARXIGA 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily.
In patients with volume depletion, correcting this condition prior to initiation of FARXIGA is recommended [see Warnings and Precautions (5.1), Use in Specific Populations (8.5, 8.6), and Patient Counseling Information (17)].
Patients with Renal Impairment
Assessment of renal function is recommended prior to initiation of FARXIGA therapy and periodically thereafter.
Initiation of FARXIGA is not recommended in patients with an eGFR less than 60 mL/min/1.73 m2.
No dose adjustment is needed in patients with mild renal impairment (eGFR of 60 mL/min/1.73 m2 or greater).
FARXIGA is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m2[see Contraindications (4)].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Farxiga (dapagliflozin)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 64 Reviews – Add your own review/rating
- Drug class: SGLT-2 inhibitors